Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HOTH - Hoth Therapeutics Inc


Previous close
0.7
0   0%

Share volume: 40,905
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$0.70
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
21%
Profitability 25%
Dept financing 3%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-8.58%
1 Month
3.57%
3 Months
-40.69%
6 Months
-46.62%
1 Year
-68.46%
2 Year
-93.69%
Key data
Stock price
$0.70
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.58 - $3.37
52 WEEK CHANGE
-$0.68
MARKET CAP 
4.791 M
YIELD 
N/A
SHARES OUTSTANDING 
6.904 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.78
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$73,300
AVERAGE 30 VOLUME 
$285,180
Company detail
CEO:
Region: US
Website:
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio

Recent news